Niagen Bioscience, Inc. (NAGE) Income Statement
NAGE 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNAGE revenue and net income
Where NAGE's revenue goes
2025Each bar shows an amount and its share of revenue. NAGE kept 13.4% of revenue as net income.
NAGE profit margins
NAGE growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +29.9% | +21.6% | +16.9% | +21.9% |
| Gross profit | +35.1% | +24.8% | +18.7% | +27.1% |
| Operating income | +85.0% | — | — | — |
| Net income | +103.3% | — | — | — |
| EPS (diluted) | +41.7% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NAGE quarterly EPS vs estimates
Niagen Bioscience beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 4, 2026 (estimate $0.00).
NAGE income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M | $59.3M | $46.3M | $31.6M | $21.2M | $21.7M |
| Cost of revenue | $46.2M | $38.0M | $32.8M | $29.3M | $26.0M | $24.0M | $20.5M | $15.5M | $10.7M | $11.3M |
| Gross profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M | $35.3M | $25.8M | $16.1M | $10.5M | $10.4M |
| Research & development | $6.3M | $6.0M | $5.0M | $4.8M | $3.8M | $3.4M | $4.4M | $5.5M | $4.0M | $2.5M |
| Sales, general & admin | $62.6M | $47.8M | $51.4M | $56.6M | $64.7M | $51.7M | $52.5M | $43.7M | $22.1M | $10.8M |
| Total operating expenses | $68.9M | $53.9M | $56.4M | $61.4M | $68.6M | $55.1M | $57.1M | $49.2M | $26.9M | $13.3M |
| Operating income | $14.3M | $7.7M | −$5.6M | −$18.6M | −$27.1M | −$19.9M | −$31.3M | −$33.2M | −$16.4M | −$2.9M |
| Interest income | $2.1M | $1.1M | $661,000 | $3,000 | — | — | — | — | — | — |
| Interest expense | — | — | — | — | $55,000 | $71,000 | $847,000 | $79,000 | $153,000 | $371,899 |
| Income before taxes | $18.2M | $8.9M | −$4.9M | −$16.5M | −$27.1M | −$19.9M | −$32.1M | −$33.3M | −$16.5M | −$3.6M |
| Income taxes | $810,000 | $305,000 | — | — | — | — | — | — | — | — |
| Net income | $17.4M | $8.6M | −$4.9M | −$16.5M | −$27.1M | −$19.9M | −$32.1M | −$33.3M | −$11.4M | −$2.9M |
| EBITDA | $19.6M | $10.3M | −$3.2M | −$14.7M | −$25.4M | −$18.3M | −$29.8M | −$32.3M | −$15.7M | −$2.5M |
| EPS (diluted) | $0.17 | $0.12 | −$0.07 | −$0.23 | −$0.41 | −$0.33 | −$0.56 | −$0.61 | −$0.34 | −$0.08 |
| Gross margin | 64.3% | 61.8% | 60.8% | 59.4% | 61.5% | 59.5% | 55.7% | 50.9% | 49.4% | 48.0% |
| Operating margin | 11.0% | 7.8% | −6.7% | −25.9% | −40.1% | −33.5% | −67.6% | −105.1% | −77.2% | −13.4% |
| Net margin | 13.4% | 8.6% | −5.9% | −23.0% | −40.2% | −33.6% | −69.4% | −105.6% | −53.7% | −13.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.8M | $31.5M | $33.8M | $34.0M | $31.1M | $30.5M | $29.1M | $25.6M | $22.7M | $22.2M | $21.2M | $19.5M |
| Cost of revenue | $10.5M | $11.5M | $12.1M | $12.1M | $10.9M | $11.2M | $10.9M | $9.3M | $9.0M | $8.7M | $8.3M | $7.5M |
| Gross profit | $19.3M | $20.0M | $21.7M | $21.9M | $20.2M | $19.3M | $18.2M | $16.2M | $13.7M | $13.5M | $12.9M | $12.0M |
| Research & development | $1.5M | $1.5M | $1.7M | $1.8M | $1.6M | $1.3M | $1.3M | $1.3M | $1.3M | $2.1M | $1.2M | $1.2M |
| Sales, general & admin | $17.1M | $16.9M | $17.9M | $15.9M | $15.5M | $13.3M | $9.8M | $13.3M | $12.6M | $12.1M | $11.9M | $11.9M |
| Total operating expenses | $18.6M | $18.4M | $19.6M | $17.7M | $17.0M | $14.6M | $11.1M | $14.6M | $13.9M | $14.2M | $13.1M | $13.1M |
| Operating income | $700,000 | $1.6M | $2.1M | $4.2M | $3.2M | $4.8M | $7.1M | $1.6M | −$256,000 | −$731,000 | −$168,000 | −$1.1M |
| Interest income | $372,000 | $375,000 | $552,000 | $564,000 | $552,000 | $459,000 | $373,000 | $276,000 | $241,000 | $239,000 | — | — |
| Income before taxes | $1.1M | $6.7M | $4.4M | $4.8M | $3.7M | $5.2M | $7.5M | $1.9M | −$15,000 | −$492,000 | $114,000 | −$959,000 |
| Income taxes | $106,000 | $417,000 | $292,000 | $222,000 | $128,000 | $168,000 | $305,000 | — | — | — | — | — |
| Net income | $963,000 | $6.3M | $4.1M | $4.6M | $3.6M | $5.1M | $7.2M | $1.9M | −$15,000 | −$492,000 | $114,000 | −$959,000 |
| EBITDA | $1.2M | $7.2M | $4.8M | $5.2M | $4.1M | $5.6M | $7.8M | $2.2M | $355,000 | −$102,000 | $487,000 | −$511,000 |
| EPS (diluted) | $0.01 | $0.02 | $0.03 | $0.05 | $0.04 | $0.05 | $0.09 | $0.02 | $0.02 | −$0.01 | $0.00 | −$0.01 |
| Gross margin | 64.8% | 63.5% | 64.1% | 64.5% | 65.0% | 63.4% | 62.5% | 63.5% | 60.2% | 60.7% | 61.0% | 61.4% |
| Operating margin | 2.4% | 5.0% | 6.2% | 12.5% | 10.2% | 15.7% | 24.4% | 6.3% | −1.1% | −3.3% | −0.8% | −5.9% |
| Net margin | 3.2% | 20.1% | 12.2% | 13.5% | 11.6% | 16.6% | 24.6% | 7.3% | −0.1% | −2.2% | 0.5% | −4.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NAGE's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NAGE financial results
In fiscal year 2025 (ended December 31, 2025), Niagen Bioscience reported revenue of $129.4 million, up 29.9% from the year before. It had net income of $17.4 million (up 103.3%), a net profit margin of 13.4%. Diluted earnings per share came to $0.17. Over five years revenue grew at an average rate of 16.9% a year.
See the NAGE stock overview for the latest quote and news, or the NAGE chart for price history and technical indicators.
NAGE income statement FAQ
What is Niagen Bioscience's annual revenue?
Niagen Bioscience reported total revenue of $129.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 29.9% from $99.6 million the previous year.
Is Niagen Bioscience profitable?
Yes. Niagen Bioscience reported net income of $17.4 million in fiscal 2025, a net profit margin of 13.4%; its operating margin was 11.0%.
What is Niagen Bioscience's gross margin?
Niagen Bioscience's gross margin was 64.3% in fiscal 2025: for every $100 of revenue, Niagen Bioscience kept $64 after the direct cost of its products and services.
How much does Niagen Bioscience spend on research and development?
Niagen Bioscience spent $6.3 million on research and development in fiscal 2025, 4.9% of revenue.
How fast is Niagen Bioscience growing?
Revenue grew 16.9% a year on average over the last five fiscal years, from $59.3 million to $129.4 million.
What are Niagen Bioscience's earnings per share?
Niagen Bioscience earned $0.17 per diluted share in fiscal 2025, compared with $0.12 a year earlier.
When will Niagen Bioscience report its next earnings?
Niagen Bioscience is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Niagen Bioscience's fiscal year end?
Niagen Bioscience's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.